Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Saved in:
| Title: | Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. |
|---|---|
| Authors: | Gisslinger H; Department of Internal Medicine I, Division of Haematology and Blood Coagulation, Medical University Vienna, Vienna, Austria. Electronic address: heinz.gisslinger@meduniwien.ac.at., Klade C; AOP Orphan Pharmaceuticals AG, Vienna, Austria., Georgiev P; University Multiprofile Hospital for Active Treatment 'Sveti Georgi', Clinic of Haematology, Medical University of Plovdiv, Plovdiv, Bulgaria., Krochmalczyk D; Teaching Unit of the Haematology Department, University Hospital in Krakow, Krakow, Poland., Gercheva-Kyuchukova L; Multiprofile Hospital for Active Treatment 'Sveta Marina', Clinical Haematology Clinic, Varna, Bulgaria., Egyed M; Department of Internal Medicine II, Kaposi MorCounty Teaching Hospital, Kaposvar, Hungary., Rossiev V; Samara Kalinin Regional Clinical Hospital, Samara, Russia., Dulicek P; Department of Clinical Haematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Illes A; Department of Haematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Pylypenko H; Department of Haematology, Regional Treatment and Diagnostics Haematology Centre, Cherkasy Regional Oncology Centre, Cherkasy, Ukraine., Sivcheva L; Multiprofile Hospital for Active Treatment-HristoBotev, First Department of Internal Medicine, Vratsa, Bulgaria., Mayer J; Clinic of Internal Medicine-Haematology and Oncology, University Hospital Brno, Brno, Czech Republic., Yablokova V; Yaroslavl Regional Clinical Hospital, Department of Haematology, Yaroslavl, Russia., Krejcy K; AOP Orphan Pharmaceuticals AG, Vienna, Austria., Grohmann-Izay B; AOP Orphan Pharmaceuticals AG, Vienna, Austria., Hasselbalch HC; Department of Haematology, Zealand University Hospital, Roskilde, University of Copenhagen, Denmark., Kralovics R; Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Kiladjian JJ; Université de Paris, CIC 1427, Inserm, F-75010, Paris, France; Centre d'Investigations Cliniques, AP-HP, Hopital Saint-Louis, F-75010, Paris, France. |
| Corporate Authors: | PROUD-PV Study Group |
| Source: | The Lancet. Haematology [Lancet Haematol] 2020 Mar; Vol. 7 (3), pp. e196-e208. Date of Electronic Publication: 2020 Jan 31. |
| Publication Type: | Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
